HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW to Canvass Drug Makers’ Opinions on Real-World Roles of “3 Key Officers”: Pharma Safety Head
July 27, 2016
-
REGULATORY ICH Clinical Trial Guidelines Allow Flexibility on Number of Japanese Subjects Needed: PMDA Official
July 26, 2016
-
REGULATORY MRSA Infections Add 190 Billion Yen Annually to Medical Expenditure at DPC Hospitals: MHLW Study Group
July 25, 2016
-
ACADEMIA Japanese Society of Nephrology Aims to Promote Development through “Surrogate Endpoints”; Hopes to Draft Guidelines in FY2017
July 22, 2016
-
REGULATORY PMDA to Announce Evaluation Policy on Diagnosis Using Next-Generation Sequencers
July 21, 2016
-
ACADEMIA New Atherosclerosis Guidelines Likely to Add PCSK9 Inhibitors for Primary Prevention of CAD in Familial Hypercholesterolemia
July 20, 2016
-
REGULATORY CDISC Therapeutic Area Standards “Can Be Used in Japan”: MHLW Study Group
July 19, 2016
-
REGULATORY Generics Should Vie on “Quality and Attractiveness”: MHLW Pharma Bureau Chief
July 15, 2016
-
REGULATORY More Companies Interested in Supporting Academia Research from the Seeds Stage: AMED Official
July 14, 2016
-
REGULATORY MHLW to Set Prerequisites for Patients, Physicians to Optimize Innovative Drug Use: Pharma Bureau Chief
July 13, 2016
-
REGULATORY AMED Aims to Facilitate Drug Makers’ Access to Knowledge at Research Institutions: President
July 12, 2016
-
REGULATORY MHLW to Put Expensive Drug Issue Up for Chuikyo Discussion ASAP: Medical Economics Division Chief
July 11, 2016
-
REGULATORY “New Rules” for Expensive Drugs Could Impact Business Models: Health Insurance Bureau Chief
July 8, 2016
-
BUSINESS Kyorin Anticipates Annual Growth of “at Least 3%” through New Drugs Despite Patent Loss for Kipres: President
July 7, 2016
-
BUSINESS Delving into Securities Filings - 3: Six Companies Report Higher Pay, More Employees
July 6, 2016
-
BUSINESS Delving into Securities Filings - 2: Average Annual Pay at 3 Generic Majors Tops 7 Mil. Yen
July 5, 2016
-
BUSINESS Delving into Securities Filings - 1: 1st and 2nd-Tier Makers Continue to Shed Jobs as Generic Peers See Rise in Workforce
July 4, 2016
-
BUSINESS Filing for 1st Japan-Made Nucleic Acid Expected by Year-End If PIII Yields Positive Data
July 1, 2016
-
BUSINESS Nichi-Iko Aims for 20% Share of Generic Market in “80% Generic Era”: President
June 30, 2016
-
ACADEMIA MHLW Study Group Aims to Formulate Guidelines for Treatment of Skeletal Dysplasias in FY2017
June 29, 2016
ページ
In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…